T.Man Pharmaceutical PCL (BKK:TMAN)
Thailand
· Delayed Price · Currency is THB 13.00
0.00 (0.00%)
At close: Mar 9, 2026
T.Man Pharmaceutical PCL Income Statement
Financials in millions THB. Fiscal year is January - December.
Millions THB. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 |
| Operating Revenue | 2,506 | 2,213 | 1,972 | 2,017 | 1,260 | Upgrade
|
| Other Revenue | 19.94 | 13.35 | 7.81 | 8.05 | 3.43 | Upgrade
|
| Revenue | 2,526 | 2,226 | 1,980 | 2,025 | 1,263 | Upgrade
|
| Revenue Growth (YoY) | 13.48% | 12.42% | -2.20% | 60.26% | 40.25% | Upgrade
|
| Cost of Revenue | 1,338 | 1,133 | 1,003 | 923.57 | 861.26 | Upgrade
|
| Gross Profit | 1,188 | 1,093 | 976.84 | 1,101 | 402.08 | Upgrade
|
| Selling, General & Admin | 597.11 | 546.65 | 496.43 | 452.32 | 313.35 | Upgrade
|
| Operating Expenses | 603.04 | 543.35 | 451.8 | 492.88 | 321.07 | Upgrade
|
| Operating Income | 584.79 | 549.98 | 525.04 | 608.21 | 81.01 | Upgrade
|
| Interest Expense | -28.44 | -18.63 | -14.85 | -16.98 | -7.18 | Upgrade
|
| EBT Excluding Unusual Items | 556.35 | 531.36 | 510.19 | 591.23 | 73.83 | Upgrade
|
| Other Unusual Items | -107.06 | - | - | - | - | Upgrade
|
| Pretax Income | 613.81 | 531.36 | 510.19 | 591.23 | 73.83 | Upgrade
|
| Income Tax Expense | 90.74 | 80.65 | 79.1 | 118.71 | 17.44 | Upgrade
|
| Earnings From Continuing Operations | 523.07 | 450.7 | 431.09 | 472.52 | 56.39 | Upgrade
|
| Minority Interest in Earnings | -0 | -0 | -0 | - | - | Upgrade
|
| Net Income | 523.07 | 450.7 | 431.09 | 472.52 | 56.39 | Upgrade
|
| Net Income to Common | 523.07 | 450.7 | 431.09 | 472.52 | 56.39 | Upgrade
|
| Net Income Growth | 16.06% | 4.55% | -8.77% | 737.91% | -5.84% | Upgrade
|
| Shares Outstanding (Basic) | 400 | 343 | 275 | 250 | 72 | Upgrade
|
| Shares Outstanding (Diluted) | 400 | 343 | 275 | 250 | 72 | Upgrade
|
| Shares Change (YoY) | 16.47% | 24.68% | 10.30% | 246.21% | 8.20% | Upgrade
|
| EPS (Basic) | 1.31 | 1.31 | 1.56 | 1.89 | 0.78 | Upgrade
|
| EPS (Diluted) | 1.31 | 1.31 | 1.56 | 1.89 | 0.78 | Upgrade
|
| EPS Growth | -0.35% | -16.14% | -17.29% | 142.02% | -12.98% | Upgrade
|
| Free Cash Flow | 110 | 345.71 | 62.15 | 289.02 | 196.49 | Upgrade
|
| Free Cash Flow Per Share | 0.28 | 1.01 | 0.23 | 1.16 | 2.72 | Upgrade
|
| Dividend Per Share | 0.320 | 0.200 | 0.036 | - | - | Upgrade
|
| Dividend Growth | 60.00% | 455.56% | - | - | - | Upgrade
|
| Gross Margin | 47.02% | 49.12% | 49.33% | 54.38% | 31.83% | Upgrade
|
| Operating Margin | 23.15% | 24.71% | 26.52% | 30.04% | 6.41% | Upgrade
|
| Profit Margin | 20.71% | 20.25% | 21.77% | 23.34% | 4.46% | Upgrade
|
| Free Cash Flow Margin | 4.35% | 15.53% | 3.14% | 14.27% | 15.55% | Upgrade
|
| EBITDA | 700.72 | 645.11 | 611.56 | 678.68 | 148.29 | Upgrade
|
| EBITDA Margin | 27.74% | 28.98% | 30.89% | 33.52% | 11.74% | Upgrade
|
| D&A For EBITDA | 115.93 | 95.12 | 86.52 | 70.48 | 67.28 | Upgrade
|
| EBIT | 584.79 | 549.98 | 525.04 | 608.21 | 81.01 | Upgrade
|
| EBIT Margin | 23.15% | 24.71% | 26.52% | 30.04% | 6.41% | Upgrade
|
| Effective Tax Rate | 14.78% | 15.18% | 15.50% | 20.08% | 23.62% | Upgrade
|
| Revenue as Reported | 2,691 | 2,226 | 1,980 | 2,025 | 1,263 | Upgrade
|
| Advertising Expenses | 101 | 113 | 97 | 89 | 52 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.